· myBETAapp™: Free Android app ( ★, 5,+ downloads) → Bayer’s myBETAapp™ and BETACONNECT™ help to support your treatment experience Bayer’s myBETAapp™ can help support /5(). · Brazil myOffice. This application is connected with Brazil’s SFDC ORG. This application will be used by Brazil’s sales rep in order to get more information about our master data; market and buying data of our customers. With this data our sales rep will be able to strengthen the relationship with our customers and will also take market. · Download myBETAapp™ and enjoy it on your iPhone, iPad, and iPod touch. Bayer’s myBETAapp™ can help support your treatment experience. myBETAapp™ is designed to assist you with managing your injections. It allows you to record your injection information manually or by connecting with the BETACONNECT™ autoinjector/5(27).
Download myBETAapp™ apk for Android. Bayer's myBETAapp™ and BETACONNECT™ help to support your treatment experience. The myBETAapp will be available for free download at the Apple app store, Google Play or bltadwin.ru in mid-July. Patients enrolled in BETAPLUS. The myBETAapp will be available for free download at the Apple app store, Google Play or bltadwin.ru in mid-July. Patients enrolled in BETAPLUS ®, Bayer's comprehensive patient support program, can speak directly to a BETA Nurse, who is specially trained in MS.
Download myBETAapp™ and enjoy it on your iPhone, iPad, and iPod touch. Bayer’s myBETAapp™ can help support your treatment experience. myBETAapp™ is designed to assist you with managing your injections. myBETAapp™ Instructions for Use Find a link for the app on bltadwin.ru or download and install the app from the Apple App Store (Apple iOS devices) or. myBETAapp™ is designed to assist you with managing your injections. It allows you to record your injection information manually or by connecting with the BETACONNECT™ autoinjector. The app can only be used by patients who are at least 18 years old and have been prescribed Bayer’s treatment for relapsing-remitting multiple sclerosis.
0コメント